ArticleFrontiers in oncology2025
Impact of adjuvant chemotherapy delay on overall survival in early-stage breast cancer: a retrospective analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Early-Stage Breast Cancer (EBC), there is no clear consensus on the ideal window for initiation of adjuvant chemotherapy from the time of definitive surgery. Furthermore, there is a paucity of data on the effectiveness of late chemotherapy. Herein, we aim to assess the effect of delays in adjuvant chemotherapy on overall survival (OS) and to investigate whether there could be a role and remaining effectiveness of late adjuvant chemotherapy compared to no chemotherapy. Methods: A retrospective cohort study was conducted utilizing data from the National Cancer Database (NCDB), focusing on patients with EBC from 2010 to 2020. Univariate and multivariate Cox regression analyses were employed. Propensity score matching (PSM) (1:1) was performed between the late and no chemotherapy groups to balance baseline characteristics. Results: N = 326,322 female patients, with a median age of 55 years (Range 47.0-62.0), were identified. Patients were distributed as follows in Group 1 (Adjuvant Chemo < 2 months since surgery N = 266,185, 81.6%), Group 2 (Adjuvant Chemo 2-4 months N = 55,063, 16.9%), Group 3 (Adjuvant Chemo 4-6 months n = 3,749, 1.15%), and Group 4 (Adjuvant Chemo given > 6 months N = 1,325, 0.4%). Multivariate analysis showed that patients in Groups 2,3,4 had worse OS compared to Group 1 (HR 1.28, 95% CI 1.20-1.36, p<0.0001; HR 1.53, 95% CI 1.27-1.84, p<0.0001; and HR 1.46, 95% CI 1.09-1.96, p=0.0104, respectively), indicating that the ideal period to start chemotherapy is within the first 2 months after surgery. When comparing the Late chemotherapy (Group 4) versus a Control Group of patients who declined recommended adjuvant chemotherapy, multivariate analysis indicated that patients in the control group experienced significantly worse OS compared to the late chemotherapy group (HR 1.55, 95% CI 1.13-2.14, p = 0.006). Conclusion: Systemic adjuvant chemotherapy given within < 2 months period since definitive surgery provides an optimal survival advantage. Notably, patients receiving late adjuvant chemotherapy > 6 months can still derive some benefit compared to those without treatment, making it a viable, though suboptimal, treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.